Autolus Therapeutics (NASDAQ:AUTL) Reaches New 1-Year Low – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low on Monday . The stock traded as low as $1.92 and last traded at $1.97, with a volume of 124566 shares trading hands. The stock had previously closed at $2.03.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics currently has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Performance

The company has a 50-day moving average of $2.37 and a 200 day moving average of $3.32. The firm has a market cap of $508.23 million, a P/E ratio of -1.58 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the company earned ($0.26) earnings per share. Sell-side analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently modified their holdings of AUTL. Millennium Management LLC raised its holdings in shares of Autolus Therapeutics by 113.7% in the second quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock valued at $2,829,000 after buying an additional 432,503 shares during the last quarter. Exchange Traded Concepts LLC increased its position in Autolus Therapeutics by 9.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after acquiring an additional 3,740 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares during the last quarter. Privium Fund Management B.V. lifted its position in shares of Autolus Therapeutics by 15.6% during the third quarter. Privium Fund Management B.V. now owns 185,639 shares of the company’s stock worth $674,000 after purchasing an additional 25,000 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Autolus Therapeutics during the third quarter valued at approximately $1,082,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.